GlassScriptPhysician profile
Anne Strickland
NPI 1174156244
$3,953.10
in general payments reported to CMS, 2019-2025
35 companies · $721 in 2025
The $721 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $748 · 2022: $889 · 2023: $939 · 2024: $655 · 2025: $721.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,316.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,316.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $519.67 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $441.32 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $353.53 | 2021-2025 | Breztri, Wainua, Farxiga |
| Lilly USA, LLC | $342.40 | 2021-2024 | Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $279.68 | 2021-2025 | |
| Medtronic, INC. | $207.77 | 2025 | Corevalve Evolut R |
| Pfizer INC. | $173.37 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $161.35 | 2024-2025 | Evkeeza |
| United Therapeutics Corporation | $147.32 | 2024-2025 | Remodulin, Orenitram, Tyvaso |
| Merck Sharp & Dohme LLC | $122.44 | 2021-2025 | Verquvo |
| Novartis Pharmaceuticals Corporation | $112.71 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $106.96 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $83.56 | 2022 | |
| Idorsia Pharmaceuticals US INC | $80.08 | 2022-2024 | Quviviq |
| Amarin Pharma, INC. | $77.16 | 2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $76.43 | 2021 | |
| Glaxosmithkline, LLC. | $67.35 | 2022 | |
| Astellas Pharma US INC | $66.42 | 2021-2024 | Veozah |
| Biohaven Pharmaceuticals, INC. | $54.71 | 2021 | |
| Esperion Therapeutics, INC. | $51.08 | 2021-2025 | Nexletol |
| Phathom Pharmaceuticals, INC. | $47.91 | 2024 | Voquezna |
| Supernus Pharmaceuticals, INC. | $45.20 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $43.63 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $40.85 | 2025 | Lifevest |
| Ibsa Pharma INC. | $38.76 | 2022 | |
| Amgen INC. | $34.22 | 2024 | Repatha |
| Arbor Pharmaceuticals, INC. | $27.11 | 2021 | |
| Boston Scientific Corporation | $26.79 | 2024 | Watchman Access System |
| Axsome Therapeutics, INC. | $23.94 | 2023 | Auvelity |
| Edwards Lifesciences Corporation | $23.77 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.80 | 2023 | Xifaxan |
| Eisai INC. | $16.17 | 2022 | |
| Alnylam Pharmaceuticals INC. | $15.73 | 2025 | Amvuttra |
| Scpharmaceuticals INC. | $15.07 | 2024 | |
| Genentech USA, INC. | $11.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Strickland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.